Novartis reports one year results of Phase III MERLIN study evaluating BEOVU® every four week dosing and provides update on BEOVU clinical program

Novartis reports one year results of Phase III MERLIN study evaluating BEOVU® every four week dosing and provides update on BEOVU clinical program

May 28, 2021
Source URL: https://www.novartis.com/us-en/news/media-releases/novartis-reports-one-year-results-phase-iii-merlin-study-evaluating-beovu-every-four-week-dosing-and-provides-update-beovu-clinical-program-0

List of links present in page